Evidence map›Paper›PMID 41738638›Full record

Trial reportClinical and translational gastroenterology2026

Dynamics in Circulating Immune Cell Subsets After Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection.

Lotte Lindgreen Eriksen, Sidsel Støy, Mette Mejlby Hansen, Emma Porsborg Gatten, Christian Erikstrup, Jens Kelsen, Benjamin H Mullish, Julian R Marchesi, Karen Louise Thomsen, Jens Frederik Dahlerup and 2 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Clinical and translational gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lotte Lindgreen EriksenDepartment of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0002-2610-2051
Sidsel StøyDepartment of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
Mette Mejlby HansenDepartment of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
Emma Porsborg GattenDepartment of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
Christian ErikstrupDepartment of Clinical Medicine, Aarhus University, Aarhus Denmark.
Jens KelsenDepartment of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
Benjamin H MullishDivision of Digestive Diseases, Department of Metabolism, Digestion, and Reproduction, Faculty of Medicine, Imperial, London, UK.
Julian R MarchesiDivision of Digestive Diseases, Department of Metabolism, Digestion, and Reproduction, Faculty of Medicine, Imperial, London, UK.
Karen Louise ThomsenDepartment of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
Jens Frederik DahlerupDepartment of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
Simon Mark Dahl BaunwallDepartment of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
Christian Lodberg HvasDepartment of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.

Funding

Innovationsfonden 8056-00006BNovo Nordisk Fonden NNF22OC0074080
6 · The paper itself

Abstract

introductionFecal microbiota transplantation (FMT) is effective for recurrent Clostridioides difficile infection (rCDI). Adverse reactions to FMT occur early, and cellular immune responses after FMT may contribute to effects and reactions. We compared early changes in peripheral immune cell subsets and clinical outcomes in patients with rCDI who received either FMT and antibiotics or antibiotics alone in a randomized trial.

methodsThirty-five patients with rCDI were randomized to vancomycin and FMT (n = 20) or vancomycin alone (n = 15). Blood samples were drawn before (wk0) and 1 week (wk1) after treatment. In 3 additional patients, blood samples were drawn before and 24 hours and wk1 after FMT. Adaptive and innate immune cell subsets and gut-homing memory (CD45RO + integrinβ7 + ) and effector (CD45RO - integrinβ7 + ) T cells were analyzed by flow cytometry.

resultsFMT induced subtle changes in immune cell subsets with no clear pattern from wk0 to wk1. The Treg fraction tended to decrease after FMT, and a similar decrease at 24 hours indicated rapid T regulatory cells dynamics. Natural killer T (NKT) cells increased during the first 24 hours and returned to baseline level at wk1. Regardless of FMT, patients with clinical resolution from rCDI had a decrease in nonclassical monocytes and a shift in gut-homing memory to effector cells at wk1. DISCUSSION: In rCDI, FMT induced subtle and transient dynamics in peripheral immune cell subsets. T regulatory cells and NKT cells seemed responsive and should be further studied. Cure of Clostridioides difficile infection may be associated with an increase in circulating gut-homing T cells.

Indexed as

Clostridioides difficileClostridium InfectionsFecal Microbiota TransplantationAdultAgedAnti-Bacterial AgentsCombined Modality TherapyFemaleFlow CytometryHumansImmunologic MemoryMaleMiddle AgedNatural Killer T-CellsRecurrenceT-Lymphocytes, RegulatoryAnti-Bacterial AgentsVancomycinfecal microbiota transplantationflow cytometryimmunologyregulatoryT lymphocytes

Identifiers

PMID41738638
PMCPMC13193283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.